CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - OCULAR THERAPEUTIX INC

Financial Performance:

• As of June 30, the company holds approximately $600 million in cash, extending runway into 2028.
• Explicit financial guidance excludes the full capital costs associated with the commercialization of X-Paxly.
• No specific revenue, growth rates, or profit margin metrics were disclosed for the quarter as the company is pre-revenue for its lead asset.
• The company indicated flexibility regarding funding the launch, potentially utilizing equity, debt, royalty mechanisms, or ex-US partnerships, though no specific capital raise plan was detailed.

Guidance and Future Outlook:

• Targeting a New Drug Application (NDA) submission in the fourth quarter under the 505(b)(2) regulatory pathway.
• The submission will rely on a single adequate and well-controlled trial (SOL1) demonstrating superiority, supported by confirmatory evidence.
• Management expresses high confidence in the regulatory timeline, having cleared Type C and pre-NDA meetings with the FDA, and anticipates an advisory committee (Adcom) is unlikely.
• The company is proceeding with commercialization preparations, asserting it has scaled up the necessary team and infrastructure for a US launch.

Business Segments and Product Lines:

• X-Paxly (SOL-1): A tunable hydrogel TKI agent for wet AMD showing statistical superiority over standard anti-VEGF therapy; currently the primary strategic focus.
• Regulatory Strategy: Successfully formalized a single-trial approval pathway with the FDA.
• SOLAR Study: Extended to assess superiority vs. aflibercept 8mg at week 96 and extended masking; delayed from Q3 to Q4 to avoid major amendments that could disrupt the accelerated review timeline.
• Pipeline Positioning: Defined as a "maintenance" drug, distinct from "bolus" injections used by competitors.

Market and Competitive Landscape:

• Competitor Setback: iPoint missed non-inferiority endpoints in two consecutive Phase 3 trials, effectively removing a competitor in the maintenance TKI space for Ocular.
• Kodiak/ALX-101: Tarkosamab showed non-inferiority to aflibercept with 54% of patients on 6-month dosing; management views this as a bolus competitor, not a direct maintenance rival, and notes incomplete data regarding patient selection and total injection burden.
• Market Dynamics: Management asserts a monopoly in the "maintenance" drug category for wet AMD following iPoint's failure.
• Market Critique: Cites a lack of disease stratification and biomarkers in ophthalmology compared to oncology/rheumatology, arguing that standard "mix-and-match" trial designs lead to failures (citing iPoint) rather than efficacy issues with the drug class itself.

Risks and Challenges:

• Clinical Trial Design: High sensitivity to patient selection strategies; failure to isolate treatment-naive patients or utilize proper loading phases is viewed as a primary risk factor for trial failure.
• Disease Variability: Acknowledges significant heterogeneity in wet AMD, DME, and RVO, complicating trial design without genetic or biomarker markers.
• Regulatory Uncertainty: While confident, the reliance on a single trial submission carries inherent risk, though the FDA has confirmed the evidentiary standards are met.
• Commercial Execution: Uncertainty regarding the exact capital required for the US launch, as current guidance excludes these costs.

Management Commentary and Tone:

• Tone: Highly confident and assertive; management frames the landscape as favorable due to competitors' failures and unique trial design.
• Strategic Clarity: Management emphasizes the distinction between "bolus" and "maintenance" therapies, positioning X-Paxly as the sole solution in the latter category.
• FDA Relations: Described as collaborative, supportive, and "in lockstep," with all boxes checked for the upcoming submission.
• Competitive Rebuttal: Dismissive of iPoint's failure, attributing it to trial design flaws (patient mixing) and weaker TKI potency rather than a class-wide issue.

Analyst Questions and Answers:

• iPoint Failure Analysis: Analyst asked if failure signals a TKI class risk; Management responded it is product-specific and design-specific, highlighting iPoint's inclusion of previously treated patients versus Ocular's strict treatment-naive selection.
• Competitor Kodiak Results: Analyst asked for thoughts on Tarkosamab's 6-month dosing; Management responded that without full data on injection counts and patient selection, it cannot be compared to their maintenance model.
• Regulatory Path: Analyst asked about the necessity of an Advisory Committee; Management stated none is expected as the mechanism (VEGF suppression) is established, not novel.
• Trial Amendments: Analyst questioned the trade-off of delaying SOLAR for better data; Management confirmed it was a strategic move to avoid major amendments that would reset the accelerated review clock.
• Capital Requirements: Analyst asked for launch capital specifics and funding source; Management declined specific numbers, citing guidance exclusions, but affirmed sufficient liquidity and openness to flexible capital structures.

Other Key Points:

• Management highlighted that 40% of patients drop out of current anti-VEGF therapy within the first year, with half losing vision, creating a critical need for sustainable treatment.
• X-Paxly is the first agent to ever hit a superiority endpoint against an anti-VEGF in wet AMD.
• The FDA definition of a "robust" trial is a p-value < 0.001; Ocular achieved a p-value < 0.0006.
• Management dismissed the need for a "bolus" loading phase prior to maintenance, relying instead on a specific loading protocol to select the patient population.